CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
Vivity IOL emmetropia +1 moredevice
Likely dose
Vivity IOL bilateral implantation, either with bilateral emmetropia or monovision (dominant eye emmetropia, non-dominant eye -0.50)AI-extracted
Key inclusion· 6
  • ✓Age 50 years or older
  • ✓Undergoing bilateral cataract extraction with IOL implantation
  • ✓IOL power requirement between +15.0 D and +25.0 D
  • ✓Toric IOL up to +3.00 D at IOL plane (2.06 D at corneal plane)
Key exclusion· 13
  • ✕Severe ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment, aniridia, iris atrophy, uveitis, iritis history, iris neovascularization, uncontrolled glaucoma, microphthalmos, macrophthalmos, optic nerve atrophy, macular degeneration with anticipated postop VA <20/30, advanced glaucomatous damage
  • ✕Uncontrolled diabetes
  • ✕Systemic or topical drugs known to interfere with visual performance
  • ✕Contact lens use during active treatment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05464732
NCT05464732N/ACompleted
CompareCT.gov

Visual Outcomes, Patient Satisfaction and Spectacle Independence Evaluation of the Acrysof® IQ Vivity® Intraocular Lens Targeted for Emmetropia or Nanovision.

Carolina Eyecare Physicians, LLC·interventional·Posted Jul 19, 2022·Updated Mar 24, 2025

In Brief

A clinical study evaluating Vivity IOL emmetropia and Vivity IOL monovision for Presbyopia. Completed, enrolled 33 participants across 1 site.

Detailed Summary

Current visual outcomes expectations of cataract patients are similar to those of refractive surgery patients. Their desire is to be spectacle independent for far, intermediate and near vision activities. Different options are available including: mono-vision and presbyopia correcting intraocular lenses (IOL). Presbyopia correcting IOLs include accommodative, multifocal, trifocal and extended depth of focus (EDOF) IOLs. The Vivity Extended Vision IOL is not a multifocal IOL but due to its design, it provides better intermediate and near VA compared to a monofocal IOL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia
CountriesUnited States
CollaboratorsScience in Vision

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJul 19, 2022
Enrollment StartSep 3, 2020
Primary CompletionAug 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 4.0 years ago

Interventions

Vivity IOL emmetropiadevice

The Vivity IOL will be implanted bilaterally in all subjects, tested with correction to bilateral emmetropia.

Vivity IOL monovisiondevice

The Vivity IOL will be implanted bilaterally in all subjects, tested with correction to emmetropia in the dominant eye and -0.50 in the non-dominant eye.